title: Immunotherapy for the treatment of glioblastoma.
abstract: Glioblastoma, the most aggressive primary brain tumor, thrives in a microenvironment of relative immunosuppression within the relatively immune-privileged central nervous system. Despite treatments with surgery, radiation therapy, and chemotherapy, prognosis remains poor. The recent success of immunotherapy in the treatment of other cancers has renewed interest in vaccine therapy for the treatment of gliomas. In this article, we outline various immunotherapeutic strategies, review recent clinical trials data, and discuss the future of vaccine therapy for glioblastoma.
authors.affiliation: Department of Neurology, Dartmouth Medical School and Dartmouth-Hitchcock Medical Center, Lebanon, NH.
authors.forename: Alissa A
authors.initials: AA
authors.lastname: Thomas
authors.forename: Marc S
authors.initials: MS
authors.lastname: Ernstoff
authors.forename: Camilo E
authors.initials: CE
authors.lastname: Fadul
mesh_terms: D001932:Brain Neoplasms / Q000276:immunology* / Q000628:therapy*; D005909:Glioblastoma / Q000276:immunology* / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*